3 Growth Stocks We Approach with Caution

Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle.

Luckily for you, our job at StockStory is to help you avoid short-term fads by pointing you toward high-quality businesses that can generate sustainable long-term growth. That said, here are three growth stocks climbing an uphill battle and some other opportunities you should consider instead.

Supernus Pharmaceuticals (SUPN)

One-Year Revenue Growth: +20.4%

With a diverse portfolio of eight FDA-approved medications targeting neurological conditions, Supernus Pharmaceuticals (NASDAQ:SUPN) develops and markets treatments for central nervous system disorders including epilepsy, ADHD, Parkinson's disease, and migraine.

Why Are We Wary of SUPN?

1. Annual revenue growth of 5.9% over the last five years was below our standards for the healthcare sector
2. Revenue base of $776.9 million puts it at a disadvantage compared to larger competitors exhibiting economies of scale
3. Eroding returns on capital from an already low base indicate that management’s recent investments are destroying value

Supernus Pharmaceuticals is trading at $51.18 per share, or 3.3x forward price-to-sales. To fully understand why you should be careful with SUPN, check out our full research report (it’s free).

Reinsurance Group of America (RGA)

One-Year Revenue Growth: +17.1%

Operating behind the scenes of the insurance industry since 1973, Reinsurance Group of America (NYSE:RGA) provides life and health reinsurance services to insurance companies, helping them manage risk and meet regulatory requirements.

Why Are We Cautious About RGA?

1. Outsized scale creates growth headwinds as its 2.1% annualized net premiums earned increases over the last two years underperformed other financial institutions
2. Incremental sales over the last two years were less profitable as its 7.8% annual earnings per share growth lagged its revenue gains
3. Book value per share is projected to decrease by 3.9% over the next 12 months as capital generation weakens

Reinsurance Group of America’s stock price of $210.55 implies a valuation ratio of 1x forward P/B. Dive into our free research report to see why there are better opportunities than RGA.

Black Stone Minerals (BSM)

One-Year Revenue Growth: +21.3%

With roots dating to the late 1800s when railroads were expanding westward and land grants were common, Black Stone Minerals (NYSE:BSM) owns oil and natural gas mineral rights across the U.S., earning royalties when energy companies drill on its land.

Why Is BSM Not Exciting?

1. Subscale operations are evident in its revenue base of $470 million, meaning it has fewer distribution channels than its larger rivals
2. Efficiency has decreased over the last five years as its EBITDA margin fell by 28.1 percentage points

At $13.84 per share, Black Stone Minerals trades at 13x forward P/E. Read our free research report to see why you should think twice about including BSM in your portfolio.

High-Quality Stocks for All Market Conditions

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren't just high-quality businesses. Something is happening with them right now. Elite fundamentals meeting near-term momentum - both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week's Strong Momentum stocks - FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.